Evidence map›Paper›PMID 39987140›Full record

ArticleCell communication and signaling : CCS2025

NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer.

Ruoxin Du, Changqing Cao, Dong Fan, Guodong Li, Shuangpeng Pu, Xinyao Xu, Mengmeng Liu, Gege Shi, Yuxin Wu, Qiang Hao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruoxin Du *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, 710032, Xi'an, P. R. China.
Changqing Cao *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, 710032, Xi'an, P. R. China.
Dong Fan *Department of General Surgery, The Second Affiliated Hospital of The Fourth Military Medical University, 710038, Xi'an, P. R. China.
Guodong LiCollege of Life Science, Northwest University, Xi'an, 710069, P. R. China.
Shuangpeng PuCollege of Life Science, Northwest University, Xi'an, 710069, P. R. China.
Xinyao XuCollege of Life Science, Northwest University, Xi'an, 710069, P. R. China.
Mengmeng LiuCollege of Life Science, Northwest University, Xi'an, 710069, P. R. China.
Gege ShiCollege of Life Science, Northwest University, Xi'an, 710069, P. R. China.
Yuxin WuCollege of Life Science, Northwest University, Xi'an, 710069, P. R. China.
Qiang HaoState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, 710032, Xi'an, P. R. China.
Yuan GaoState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, 710032, Xi'an, P. R. China.
Juliang ZhangDepartment of Vascular and Endocrine Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710000, China. vascularzhang@163.com.
Huadong ZhaoDepartment of General Surgery, The Second Affiliated Hospital of The Fourth Military Medical University, 710038, Xi'an, P. R. China. zhaolujy@fmmu.edu.cn.
Cun ZhangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, 710032, Xi'an, P. R. China. zhangcun@fmmu.edu.cn.

Funding

National Natural Science Foundation of China-General Program 81902678Shaanxi Research Fund for Young Stars of Science and Technology 2022KJXX-103Shaanxi Science Fund for Distinguished Young Scholars No. 2022JC-53Young Elite Scientist Sponsorship Program by CAST YESS20210177
6 · The paper itself

Abstract

Trastuzumab serves as a cornerstone of first-line therapy for HER2-positive (HER2

Indexed as

Antibody-Dependent Cell CytotoxicityBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesKiller Cells, NaturalLiposomesMolecular Targeted TherapyNanoparticlesAnimalsCell Line, TumorFemaleHumansMiceTrastuzumabTumor MicroenvironmentERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLiposomesTrastuzumabAntibody-dependent cell-mediated cytotoxicityHER2+ breast cancerNanoliposomesNatural killer cellTrastuzumab resistance

Identifiers

PMID39987140
PMCPMC11846243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.